Literature DB >> 20036445

Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.

Vincenzo Carbone1, Marco Giglio, Roland Chung, Trevor Huyton, Julian Adams, Rosanna Maccari, Rosaria Ottana, Akira Hara, Ossama El-Kabbani.   

Abstract

The structure of aldehyde reductase (ALR1) in ternary complex with the coenzyme NADPH and [5-(3-carboxymethoxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid (CMD), a potent inhibitor of aldose reductase (ALR2), was determined at 1.99A resolution. The partially disordered inhibitor formed a tight network of hydrogen bonds with the active site residues (Tyr50 and His113) and coenzyme. Molecular modelling calculations and inhibitory activity measurements of CMD and [5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid (HMD) indicated that pi-stacking interactions with several conserved active site tryptophan residues and hydrogen-bonding interactions with the non-conserved C-terminal residue Leu300 in ALR2 (Pro301 in ALR1) contributed to inhibitor selectivity. In particular for the potent inhibitor CMD, the rotameric state of the conserved residue Trp219 (Trp220 in ALR1) is important in forming a pi-stacking interaction with the inhibitor in ALR2 and contributes to the difference in the binding of the inhibitor to the enzymes. Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036445     DOI: 10.1016/j.ejmech.2009.12.019

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.

Authors:  Kun-Che Chang; Linfeng Li; Theresa M Sanborn; Biehuoy Shieh; Patricia Lenhart; David Ammar; Daniel V LaBarbera; J Mark Petrash
Journal:  J Nat Prod       Date:  2016-05-03       Impact factor: 4.050

2.  Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors.

Authors:  Muhammad Tariq Shehzad; Aqeel Imran; Abdul Hameed; Mariya Al Rashida; Marium Bibi; Maliha Uroos; Asnuzilawati Asari; Shafia Iftikhar; Habsah Mohamad; Muhammad Nawaz Tahir; Zahid Shafiq; Jamshed Iqbal
Journal:  RSC Adv       Date:  2021-05-11       Impact factor: 3.361

3.  Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies.

Authors:  Mohsinul Mulk Bacha; Humaira Nadeem; Sumera Zaib; Sadia Sarwar; Aqeel Imran; Shafiq Ur Rahman; Hafiz Saqib Ali; Muazzam Arif; Jamshed Iqbal
Journal:  BMC Chem       Date:  2021-04-27

4.  Development and exploration of novel substituted thiosemicarbazones as inhibitors of aldose reductase via in vitro analysis and computational study.

Authors:  Aqeel Imran; Muhammad Tariq Shehzad; Syed Jawad Ali Shah; Taha Al Adhami; Mark Laws; Khondaker Miraz Rahman; Rima D Alharthy; Imtiaz Ali Khan; Zahid Shafiq; Jamshed Iqbal
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

5.  Development, Molecular Docking, and In Silico ADME Evaluation of Selective ALR2 Inhibitors for the Treatment of Diabetic Complications via Suppression of the Polyol Pathway.

Authors:  Aqeel Imran; Muhammad Tariq Shehzad; Syed Jawad Ali Shah; Mark Laws; Taha Al-Adhami; Khondaker Miraz Rahman; Imtiaz Ali Khan; Zahid Shafiq; Jamshed Iqbal
Journal:  ACS Omega       Date:  2022-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.